Table 3.

Non-hematological adverse events within 4 weeks^a.

	Total (%)	Grade 3–4(%)
CRS	39 (83.0)	11 (23.4)
ICANS	2 (4.3)	1 (2.1)
ALT/AST increased	10 (21.3)	2 (4.3)
CRE increased	2 (4.3)	0
APTT/PT prolonged	10 (21.3)	0
Fibrinogen decreased	5 (10.6)	0
Acidosis	1 (2.1)	0
Hypokalemia	4 (8.5)	1 (2.1)
Hypoglycemia	2 (4.3)	0
Cephalalgia	2 (4.3)	0
Myalgia	2 (4.3)	0

^aAccording to the CTCAE grading system by the United States National Cancer Institute³⁸, and ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells³⁹.

CRS represents cytokine release syndrome, ICANS immune effector cell-associated neurotoxicity syndrome, ALT alanine aminotransferase, AST aspartate aminotransferase, CRE creatinine, APTT activated partial thromboplastin time, PT prothrombin time.

Source data is provided as a Source Data file or available at 10.6084/m9.figshare.13136078.v1.